Clostridium difficile Polysaccharide Vaccine Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing incidence and severity of Clostridium difficile-associated diarrhea (CDAD) pose significant healthcare challenges due to high morbidity, mortality, treatment failures, and high relapse rates, particularly with the emergence of the ribotype 027 strain, which produces toxic compounds and resists phagocytosis through cell surface polysaccharides, necessitating effective prevention and treatment approaches.
Innovation Solution
Development of novel Clostridium difficile cell surface polysaccharides, including their covalent chemical structures, for use in immunogenic compositions and vaccine preparations to induce an immune response, prevent infection, and treat CDAD, utilizing repeating units such as hexasaccharides and pentasaccharides linked by phosphodiester bonds, and conjugating these polysaccharides with carrier molecules to enhance immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (metronidazole, vancomycin) are used, then treatment of C. difficile infection is achieved, but treatment response becomes unpredictable and costs increase
Solution Approach 1:
The patent segments the complex bacterial cell surface into specific polysaccharide components (capsular polysaccharides and teichoic acids) that can be isolated and used as targeted immunogens, replacing the need for broad-spectrum antibiotic treatments with a specific vaccine approach
Solution Approach 2:
The patent introduces an intermediary immunogenic composition containing purified C. difficile polysaccharides that mediates the immune response, serving as a bridge between the pathogen and the host immune system to achieve protection without using antibiotics
2Object-affected harmful factors
If prophylactic antibiotics are used, then prevention of infection is attempted, but incidence of disease increases
Solution Approach 1:
Instead of using antibiotics to prevent infection (which disrupts microbiota and increases disease incidence), the patent inverts the approach by using polysaccharide-based vaccines to stimulate protective immunity without disrupting the microbial ecosystem
3Object-affected harmful factors
If patient isolation and infection control measures are implemented, then spread of C. difficile is limited, but healthcare costs increase
Solution Approach 1:
The patent applies preliminary action by developing vaccines that provide proactive immunity before exposure to C. difficile, eliminating the need for reactive isolation and infection control measures during outbreaks
4Object-generated harmful factors
If C. difficile ribotype 027 strain proliferates, then toxin production increases, but phagocytosis resistance increases
Solution Approach 1:
The patent extracts the specific capsular polysaccharide and teichoic acid components from the C. difficile cell surface that are responsible for both toxin production regulation and phagocytosis resistance, using them as targeted immunogens to overcome these protective mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these novel polysaccharides in vaccine compositions elicits a strong immune response, effectively preventing and treating CDAD, reducing the risk of zoonotic transmission, and offering a safer alternative to current treatments by targeting the bacterium's cell surface antigens.
Implementation Method 1
novel immunogenic Clostridium difficile cell surface polysaccharides... for use in immunogenic compositions and vaccine preparations to induce an immune response
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The application relates to Clostridium difficile cell surface polysaccharides, compositions comprising Clostridium difficile cell surface polysaccharides, and includes kits, methods and uses thereof.